

The Manager
Companies Announcement Platform
SIM Venture Securities Exchange

13 March 2012

Serum Institute of India Clinical Trials with SoloFlow[®] Cannula

HIGHLIGHTS:

- SoloFlow[®] Cannula used for Clinical Trials for new Influenza Vaccine
 - 28,600 SoloFlow[®] cannula already shipped to SII for first commercial order
-

Telezon Limited[®] ("the Company") is pleased to announce that following its first commercial order to the Serum Institute of India ("SII"), SII has confirmed that the Company's SoloFlow[®] cannula will be used in one of their clinical trials for a new influenza vaccine later this year. The company's safety engineered SoloFlow[®] cannula will be used to reconstitute (mix or prepare) the vaccine.

Telezon has been working closely with the SII over the last 12-18 months to deliver its SoloFlow[®] cannula for these trials. In successfully delivering our products to SII and to their specifications, the Institute has recently approved Telezon and SSB as an official vendor of the SoloFlow[®] cannula.



Figure I: "SII" Vaccine Kit

Courtesy of SII



Figure II: "SII" Syringe with SoloFlow[®] Cannula

Courtesy of SII



1 Dalmore Drive, Caribbean Business Park, Scoresby VIC 3179
PO Box 485, South Melbourne VIC 3205
Tel: 61 03 9763 8605 Fax: 61 03 9763 2714
www.telezon.com

SII is the world's largest producer of vaccines for Measles and the DTP group (Diphtheria, Tetanus & Pertussis). It is estimated that two out of every three children immunized in the world are vaccinated by a vaccine manufactured by SII. SII's range of products has been used in 140 countries across the globe. SII products have been supplied to International Health Agencies including the WHO, UNICEF and PAHO. The high service standards have resulted in several acknowledgements and appreciation from International agencies and local governments and awards from Trade authorities. (<http://www.seruminstitute.com>)

Please refer to our website for more detailed information on our products. Telezon is listed on SIM Venture Securities Exchange [www.simvse.com.au] (SIM: TLZ).

For and on behalf of Telezon Limited,

Dr Michelle Carr
Director & Company Secretary
T: 61 03 9763 8605
F: 61 03 9763 2714
www.telezon.com